Dallas-based Secretome Therapeutics announced that Deepa Prasad has been appointed chief financial officer of the biotechnology company, which develops first-in-class therapeutics derived from neonatal mesenchymal stem cells for the treatment of underserved diseases.
“Deepa brings a wealth of knowledge through her combination of investment banking, operations, and venture capital experience in the life science industry,” Vinny Jindal, president and chief executive officer of Secretome Therapeutics, said in a statement....
MORE►
